Skip to main content

T cell receptor repertoire as a prognosis marker for heat shock protein peptide complex-96 vaccine trial against newly diagnosed glioblastoma.

Publication ,  Journal Article
Zhang, Y; Mudgal, P; Wang, L; Wu, H; Huang, N; Alexander, PB; Gao, Z; Ji, N; Li, Q-J
Published in: Oncoimmunology
2020

Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults with a dismal prognosis. We previously reported that vaccination with heat shock protein peptide complex-96 (HSPPC-96) improves survival in patients with newly diagnosed GBM (NCT02122822). Especially for patients with a strong antitumor immune response after vaccination, a durable survival benefit can be achieved. Here, we conducted T cell receptor (TCR) sequencing to retrospectively examine the TCR repertoires of tumor-infiltrating lymphocytes in long-term survivors (LTS) and short-term survivors (STS). We found that LTS exhibit lower TCR repertoire diversity compared with STS, indicating the prevalence of dominant TCR clones in LTS tumors. Accordingly, the LTS group showed increased inter-patient similarity, especially among high-frequency TCR clones, implying some of these dominant clones are shared among LTS. Indeed, we discovered four TCR clones significantly enriched in the LTS group: the presence of these clones has predictive value for stratifying patients prior to vaccination. Together, these findings uncover a group of preexisting TCR clones shared in LTS that can be utilized as candidate biomarkers to select GBM patients most likely to durably respond to HSPPC-96 treatment.

Duke Scholars

Published In

Oncoimmunology

DOI

ISSN

2162-4011

Publication Date

2020

Volume

9

Issue

1

Start / End Page

1749476

Location

United States

Related Subject Headings

  • Retrospective Studies
  • Receptors, Antigen, T-Cell
  • Prognosis
  • Middle Aged
  • Male
  • Humans
  • Heat-Shock Proteins
  • Glioblastoma
  • Female
  • Cancer Vaccines
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zhang, Y., Mudgal, P., Wang, L., Wu, H., Huang, N., Alexander, P. B., … Li, Q.-J. (2020). T cell receptor repertoire as a prognosis marker for heat shock protein peptide complex-96 vaccine trial against newly diagnosed glioblastoma. Oncoimmunology, 9(1), 1749476. https://doi.org/10.1080/2162402X.2020.1749476
Zhang, Yang, Poorva Mudgal, Liuyang Wang, Haiyang Wu, Na Huang, Peter B. Alexander, Zhixian Gao, Nan Ji, and Qi-Jing Li. “T cell receptor repertoire as a prognosis marker for heat shock protein peptide complex-96 vaccine trial against newly diagnosed glioblastoma.Oncoimmunology 9, no. 1 (2020): 1749476. https://doi.org/10.1080/2162402X.2020.1749476.
Zhang Y, Mudgal P, Wang L, Wu H, Huang N, Alexander PB, et al. T cell receptor repertoire as a prognosis marker for heat shock protein peptide complex-96 vaccine trial against newly diagnosed glioblastoma. Oncoimmunology. 2020;9(1):1749476.
Zhang, Yang, et al. “T cell receptor repertoire as a prognosis marker for heat shock protein peptide complex-96 vaccine trial against newly diagnosed glioblastoma.Oncoimmunology, vol. 9, no. 1, 2020, p. 1749476. Pubmed, doi:10.1080/2162402X.2020.1749476.
Zhang Y, Mudgal P, Wang L, Wu H, Huang N, Alexander PB, Gao Z, Ji N, Li Q-J. T cell receptor repertoire as a prognosis marker for heat shock protein peptide complex-96 vaccine trial against newly diagnosed glioblastoma. Oncoimmunology. 2020;9(1):1749476.

Published In

Oncoimmunology

DOI

ISSN

2162-4011

Publication Date

2020

Volume

9

Issue

1

Start / End Page

1749476

Location

United States

Related Subject Headings

  • Retrospective Studies
  • Receptors, Antigen, T-Cell
  • Prognosis
  • Middle Aged
  • Male
  • Humans
  • Heat-Shock Proteins
  • Glioblastoma
  • Female
  • Cancer Vaccines